financetom
Business
financetom
/
Business
/
Hotel Operator Marriott Slips After Mixed Q1 Earnings
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hotel Operator Marriott Slips After Mixed Q1 Earnings
May 1, 2024 8:20 AM

Marriott International Inc ( MAR ) shares are trading lower after the company's first-quarter adjusted EPS missed estimates.

The company reported first-quarter FY24 sales growth of 6.5% year-on-year to $5.98 billion, beating the analyst consensus estimate of $5.93 billion.

Comparable systemwide constant dollar RevPAR increased 4.2% worldwide, 1.5% in the U.S. & Canada, and 11.1% in international markets, compared to the first-quarter FY23.

Total expenses declined 9% Y/Y to $5.1 billion. Adjusted EBITDA for the quarter was $1.14 billion versus $1.09 billion a year ago.

Operating margin for the quarter contracted Y/Y from 16.9% to 14.7%, with operating income increasing 8% to $876 billion.

Adjusted EPS of $2.13 missed the consensus estimate of $2.17.

The company added about 46,000 rooms globally during the first-quarter. Marriott ( MAR ) held $0.4 billion in cash and equivalents as of March 31, 2024.

In first-quarter, Marriott ( MAR ) repurchased 4.8 million shares of common stock for $1.2 billion. The company returned $1.7 billion to shareholders year-to-date through April 26.

“We are excited about the launch of MGM Collection with Marriott Bonvoy during the quarter, which added nearly 37,000 rooms to our system from our strategic agreement with MGM Resorts International," said President and CEO Anthony Capuano.

Outlook: Marriott ( MAR ) raised FY24 adjusted EPS outlook from $9.18-$9.52 to  $9.31-$9.65 versus an estimate of $10.74.

The company expects second-quarter adjusted EPS of $2.43-$2.48 against an estimate of $2.52.

Price Action: MAR shares are trading lower by 1.03% to $233.78 at last check Wednesday.

Now Read: Cannabis Advocates Say DEA’s Move Represents ‘Progress But Not Justice,’ Ends War On Medical Marijuana Patients, But Not War On Drugs

Image created using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics
Mar 19, 2024
11:02 AM EDT, 03/19/2024 (MT Newswires) -- Centogene ( CNTG ) said Tuesday it will continue to give Takeda Pharmaceutical ( TAK ) access to diagnostic testing for patients with Lysosomal Storage Disorders, or LSDs, under the companies' extended agreement. Centogene ( CNTG ) said the companies entered into the partnership to improve patient access to testing for disorders such...
Nvidia's New Chips Likely to Help Extend AI Value Chain Dominance, Analysts Say
Nvidia's New Chips Likely to Help Extend AI Value Chain Dominance, Analysts Say
Mar 19, 2024
10:58 AM EDT, 03/19/2024 (MT Newswires) -- Nvidia's ( NVDA ) new Blackwell computing platform, along with a series of artificial intelligence chips, should give the semiconductor maker a competitive edge in the AI accelerator market, multiple analysts said on Tuesday. The offerings, announced during its developer's conference in San Jose, included the B100, B200, and GB200 chips. The company's...
XPeng Fourth-Quarter Revenue Climbs, Loss Narrows; Guides Top-Line Momentum Through First Quarter
XPeng Fourth-Quarter Revenue Climbs, Loss Narrows; Guides Top-Line Momentum Through First Quarter
Mar 19, 2024
10:57 AM EDT, 03/19/2024 (MT Newswires) -- XPeng ( XPEV ) reported a sharp jump in fourth-quarter revenue and a reduced per-share loss Tuesday, with deliveries nearly tripling year over year, and guided for ongoing revenue momentum despite short-term challenges. Revenue climbed to 13.05 billion renminbi ($1.84 billion) for the three months ended Dec. 31 from 5.14 billion renminbi the...
Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance
Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance
Mar 19, 2024
10:58 AM EDT, 03/19/2024 (MT Newswires) -- Cytek Biosciences ( CTKB ) said Tuesday it has appointed William McCombe as chief financial officer, effective immediately, and reaffirmed its full-year 2024 guidance. McCombe succeeds Patrik Jeanmonod, who has served as the company's CFO since 2018. Jeanmonod has been appointed as head of corporate development analytics, the company said. The company said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved